Millennium reports 5.1% stake in Contineum Therapeutics

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported shared beneficial ownership of 1,658,349 shares of Contineum Therapeutics, Inc. Class A common stock, representing 5.1% of that class.

Rhea-AI Filing Summary

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported shared beneficial ownership of 1,658,349 shares of Contineum Therapeutics, Inc. Class A common stock, representing 5.1% of that class. The filing is a joint Schedule 13G and includes a Joint Filing Agreement dated April 16, 2026.

The filing states the disclosed shares are held by entities subject to voting and investment control by Millennium Management LLC and related managers; the filing does not assert sole voting or sole dispositive power.

Insights

Institutional Ownership Analyst

Large institutional holder reports a passive 5.1% stake in Contineum.

The Schedule 13G shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander jointly report 1,658,349 shares, with shared voting and dispositive power. The disclosure follows passive-investor reporting norms under a 13G construct.

Implications depend on holder intent and future amendments; subsequent changes would appear in later filings if the group assumes active control or increases holdings.

Corporate Governance Specialist

Joint filing and shared controls are documented; no sole power claimed.

The filing includes a Joint Filing Agreement dated April 16, 2026 and specifies shared voting/dispositive power of 1,658,349 shares. It expressly refrains from admitting beneficial ownership beyond the disclosed arrangements.

Watch for amendments that would convert this passive position to an active Schedule 13D if the group's intent or voting arrangements change.

Key Figures

Shared beneficial ownership: 1,658,349 shares Percent of class: 5.1% Form type: Schedule 13G +2 more

5 metrics

Shared beneficial ownership 1,658,349 shares Class A common stock (as reported on cover page)

Percent of class 5.1% Percent of Class A common stock (cover page)

Form type Schedule 13G Passive beneficial ownership report

Joint Filing Agreement date April 16, 2026 Exhibit I to the filing

CUSIP 21217B100 Contineum Therapeutics Class A Common Stock

Key Terms

Schedule 13G, shared dispositive power, Joint Filing Agreement

3 terms

Schedule 13G regulatory

"The filing is a joint <b>Schedule 13G</b> and includes a Joint Filing Agreement"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

shared dispositive power regulatory

"Shared Dispositive Power 1,658,349.00"

Joint Filing Agreement legal

"Exhibit I: Joint Filing Agreement, dated as of April 16, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Millennium report in Contineum Therapeutics (CTNM)?

They report shared beneficial ownership of 1,658,349 shares, representing 5.1% of Class A common stock. The amount and percentage are shown on the Schedule 13G cover information dated April 13, 2026.

Who filed the Schedule 13G for CTNM?

The filing was submitted jointly by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. A Joint Filing Agreement dated April 16, 2026 is included as an exhibit.

Does the filing claim sole voting or dispositive power over the shares?

No. The filing reports 0 sole voting power and 0 sole dispositive power, with shared voting and shared dispositive power of 1,658,349 shares as disclosed on the cover page.

Is this a passive 13G filing or an active 13D filing?

This is a Schedule 13G, indicating a passive reporting status under the form used. Any shift to active intent or control would typically trigger an amendment or conversion to Schedule 13D.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/17/2026 - 04:42 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Contineum Therapeutics, Inc.

(Name of Issuer)

Class A Common Stock, par value $0.001 per share

(Title of Class of Securities)

21217B100

(CUSIP Number)

04/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 21217B100

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,658,349.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,658,349.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,658,349.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 21217B100

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,658,349.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,658,349.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,658,349.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 21217B100

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,658,349.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,658,349.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,658,349.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Contineum Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 3565 General Atomics Court, Suite 200, San Diego, California 92121
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Class A Common Stock, par value $0.001 per share
(e)	CUSIP Number(s): 21217B100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	04/16/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	04/16/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	04/16/2026

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of April 16, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.